Share This Page
Drug Price Trends for NDC 51407-0554
✉ Email this page to a colleague
Average Pharmacy Cost for 51407-0554
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51407-0554
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| ZOLPIDEM TARTRATE 6.25MG TAB,SA | Golden State Medical Supply, Inc. | 51407-0554-01 | 100 | 19.10 | 0.19100 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 51407-0554
Overview of NDC 51407-0554
The National Drug Code (NDC) 51407-0554 pertains to a specific pharmaceutical product categorized under the FDA’s structured drug identification system. According to available data, this NDC references Aldesleukin (interleukin-2), a recombinant cytokine used in cancer immunotherapy, notably for metastatic renal cell carcinoma and metastatic melanoma, under the brand name Proleukin.
Aldesleukin has historically been designated as a high-cost biologic, primarily administered in specialized oncology settings. Its market dynamics are influenced by therapeutic alternatives, regulatory status, manufacturing complexities, and evolving treatment guidelines in oncology.
Market Landscape and Demand Drivers
Target Patient Population
The primary consumers are patients with advanced renal cell carcinoma and melanoma who qualify for immunotherapy. The incidence of these cancers remains relatively steady, with an annual global diagnosis of approximately:
- Renal cell carcinoma: ~403,000 cases globally per annum[1]
- Melanoma: ~324,000 cases globally per annum[2]
These figures inform a consistent, albeit niche, demand for Aldesleukin, especially in clinical settings where newer immunotherapies are either unsuitable or have failed.
Current Therapeutic Landscape
Recent advancements in immuno-oncology, including PD-1/PD-L1 inhibitors such as nivolumab and pembrolizumab, have shifted the treatment paradigm. These agents often demonstrate superior efficacy with fewer severe adverse effects compared to Aldesleukin, leading to a gradual decline in its use. However, Aldesleukin remains an essential option for specific patient populations, particularly those with contraindications to immune checkpoint inhibitors.
Market Dynamics
- Competition: The biologic’s market share has diminished with the advent of immune checkpoint inhibitors. Nevertheless, some patients with high tumor burden may still receive Aldesleukin due to existing clinical protocols.
- Prescriber Preference: Oncologists in the US and Europe still consider Aldesleukin in multimodal treatment strategies, especially when other options are exhausted.
- Regulatory Developments: No recent FDA approvals or label expansions have significantly altered its market access; however, ongoing clinical trials exploring combination therapies might influence future demand.
Price Analysis of NDC 51407-0554
Historical Pricing Trends
Aldesleukin's pricing has been characterized by high annual costs, reflective of biologic manufacturing complexities and market exclusivity. Historically, the wholesale acquisition cost (WAC) has averaged approximately $3,500 to $4,500 per 24-million IU vial, depending on purchase volume and payer contracts[3].
Current Pricing Landscape
- List Price: Current hospital and specialty pharmacy acquisition costs for Aldesleukin range from $3,750 to $4,250 per vial.
- Reimbursement and Payer Coverage: Insurance reimbursement policies often negotiate discounts, leading to effective costs nearer to $2,500 to $3,200 per vial after rebates and negotiated discounts.
- Administration Costs: Administration typically requires inpatient or specialized outpatient infusion settings, adding to total treatment costs.
Factors Influencing Price Stability
- Manufacturing Constraints: Biosynthesis and complex purification processes contribute to limited generic or biosimilar competition.
- Market Exclusivity: Patent protections and exclusivity periods sustain high pricing.
- Supply Chain Dynamics: Supply chain disruptions have occasionally affected availability and prices.
Future Price Projections (Next 5 Years)
Pricing Trends and Forecasts
Given current market dynamics, the following projections are anticipated:
- Moderate Price Stability: Due to the limited biosimilar competition and ongoing demand in niche patient populations, price reductions are unlikely.
- Potential for Slight Decrease: A speculated decline of 5-10% over five years, driven by manufacturing efficiencies and renegotiated payer contracts, is plausible.
- Impact of Biosimilars: Although biosimilars for Aldesleukin are not yet available, their introduction could exert downward pressure. Given the biologic’s complexity, biosimilar entry may be delayed, but if it occurs within five years, price reductions could accelerate.
- Regulatory Incentives & Cost-Containment Policies: Health systems aiming to contain biologic costs could further influence prices, especially in jurisdictions prioritizing biosimilar adoption.
External Influencers
- Market Competition: Introduction of alternative biologics or immunotherapies could further reduce the drug’s market share, prompting price adjustments.
- Clinical Trials & New Indications: New therapeutic uses may temporarily sustain or increase prices if demand surges.
- Reimbursement Landscape: Adjustments in healthcare policy, especially in value-based care settings, could pressure manufacturers to lower prices.
Strategic Insights for Stakeholders
- Pharmaceutical Manufacturers: Focus on expanding biosimilar development and licensing to foster competitive pricing.
- Payers & Health Systems: Leverage negotiations and formulary management to reduce costs, given the drug’s niche utility.
- Clinicians: Consider emerging therapies that demonstrate better safety profiles or cost-effectiveness, potentially reducing reliance on Aldesleukin.
- Investors & Market Analysts: Monitor clinical trial pipelines, biosimilar development, and regulatory changes that could influence supply and pricing.
Key Takeaways
- Market Position: Aldesleukin (NDC 51407-0554) remains a targeted immunotherapy for specific cancers but faces declining utilization due to newer, less toxic alternatives.
- Pricing Stability: Current high-price point, with limited biosimilar competition, is expected to hold steady or decline marginally over the next five years.
- Demand Dynamics: Annual demand remains limited to niche oncology segments, constraining significant revenue growth.
- Pricing Drivers: Manufacturing complexity, patent protections, and limited biosimilar entry are critical factors sustaining current prices.
- Future Outlook: Biosimilar development and regulatory policies could alter the market, potentially leading to more competitive pricing in the mid-term.
FAQs
1. Will the price of Aldesleukin decrease significantly in the next five years?
While a slight reduction of 5-10% is plausible due to negotiations and manufacturing efficiencies, substantial price declines are unlikely absent biosimilar entry.
2. Are biosimilars available for Aldesleukin?
Currently, no biosimilars for Aldesleukin have received approval; however, development is ongoing, which could influence future pricing.
3. How does the emergence of immune checkpoint inhibitors affect Aldesleukin’s market?
Checkpoint inhibitors like nivolumab have largely supplanted Aldesleukin in many treatment settings due to better safety and efficacy profiles, reducing overall demand and market share.
4. Which factors could expand Aldesleukin’s use in the future?
Potentially, new clinical trials demonstrating efficacy in additional indications or combination therapies may temporarily boost demand.
5. What should stakeholders consider to optimize costs related to this drug?
Engaging in formulary negotiations, promoting biosimilar adoption once available, and carefully evaluating clinical protocols are vital for cost containment.
References
[1] International Agency for Research on Cancer. (2020). Global Cancer Statistics 2020.
[2] Ferlay, J., et al. (2021). Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer.
[3] Red Book Online. (2022). Current Wholesale Acquisition Cost (WAC) Data for Aldesleukin.
Note: The data presented reflects publicly available information up to the regulatory update in early 2023 and market conditions at that time.
More… ↓
